USFDA concludes inspection at Natco Pharma’s Hyderabad API manufacturing plant

13 Jun 2025 Evaluate

The U.S. Food and Drug Administration (USFDA) has concluded the inspection at Natco Pharma’s API manufacturing plant located in Mekaguda, Hyderabad, India. The said inspection was conducted from June 9 to June 13, 2025. On conclusion of the inspection, the Company received 1 observation in the Form 483. 

The Company believes that the observation is procedural in nature. The Company is confident to address this observation comprehensively. The company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally. 

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

888.60 -14.95 (-1.65%)
01-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.40
Dr. Reddys Lab 1253.60
Cipla 1500.10
Zydus Lifesciences 914.50
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×